MISSISSAUGA, ON, Feb. 11, 2020 /CNW/ - At the request of the
Investment Industry Regulatory Organization of Canada (IIROC), Nuvo Pharmaceuticals Inc.
(Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian-focused
healthcare company with global reach and a diversified portfolio of
commercial products, wishes to confirm that it is not aware of any
material, undisclosed information related to the Company that would
account for the recent increase in the market price and level of
trading volume of its common shares.
About Nuvo Pharmaceuticals Inc.
Nuvo (TSX: NRI; OTCQX: NRIFF) is a Canadian focused, healthcare
company with global reach and a diversified portfolio of commercial
products. The Company targets several therapeutic areas,
including pain, allergy and dermatology. The Company's
strategy is to in-license and acquire growth-oriented,
complementary products for Canadian and international
markets. Nuvo's head office is located in Mississauga, Ontario, Canada, the
international operations are located in Dublin, Ireland and the U.S. Food and Drug
Administration (FDA), Health Canada and E.U. approved manufacturing
facility is located in Varennes,
Québec, Canada. The Varennes
facility operates in a Good Manufacturing Practices (GMP)
environment respecting the U.S, Canada and E.U. GMP regulations and is
regularly inspected by Health Canada and the FDA. For
additional information, please visit
www.nuvopharmaceuticals.com.
View original
content:http://www.prnewswire.com/news-releases/nuvo-pharmaceuticals-responds-to-market-activity-301003155.html
SOURCE Nuvo Pharmaceuticals Inc.